Abstracts tagged "SLE"

Abstract Number: 2789 • 2014 ACR/ARHP Annual Meeting
Medical Marijuana Related Outcomes in Patients with Systemic Lupus Erythematosis
Basmah Jalil¹, Wilmer Sibbitt Jr.², Romy Cabacangun³, Clifford Qualls⁴, Arthur Bankhurst⁵ and Roderick Fields⁶, ¹Internal Medicine/Rheumatology, University of New Mexico, Albuquerque, NM, ²Internal Medicine/Rheumatology, University of New Mexico HSC, Albuquerque, NM, ³Rheumatology, UNM, Albuquerque, NM, ⁴Biostatistics, UNM, Albuquerque, NM, ⁵Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, ⁶Internal Medicine/ Rheumatology, University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose Medical cannabis is used extensively in the United States, usually in the form of smoked marijuana. There is growing research regarding the immunomodulatory effects…
Abstract Number: 2185 • 2014 ACR/ARHP Annual Meeting
Alterations in B Cell Complement Processing Related to a Lupus-Associated Variant in Complement Receptor 2
Brendan M. Giles¹ and Susan A. Boackle², ¹University of Colorado School of Medicine, Aurora, CO, ²Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: We have recently identified a variant in intron 1 of complement receptor 2 (CR2/CD21) that is associated with decreased risk of lupus (rs1876453; Pmeta=4.2×10-4,…
Abstract Number: 1664 • 2014 ACR/ARHP Annual Meeting
Novel Risk Factors for Systemic Lupus Erythematosus (SLE) Flares in Patients with End-Stage Renal Disease: Is SLE in Patients with End-Stage Renal Disease a “sleeping beauty”?
Jorge Alcocer-Varela¹, Mariana Quintanar², Javier Merayo-Chalico³, Ana Barrera-Vargas¹ and Diana Gómez-Martín¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose Renal involvement in systemic lupus erythematosus (SLE) is frequent, and a high percentage of patients (~15%) develop end-stage renal disease (ESRD) even with optimal…
Abstract Number: 870 • 2014 ACR/ARHP Annual Meeting
IRF1 Influences on Histone H4 Acetylation in Systemic Lupus Erythematosus
Yiu Tak Leung¹, Lihua Shi², Kelly Maurer², Li Song², Zhe Zhang³, Michelle Petri⁴ and Kathleen E. Sullivan², ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Bioinformatics, Bioinformatics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is the classical systemic autoimmune disease. Epigenetic processes, such as posttranslational histone modifications, can regulate gene expression without altering the…
Abstract Number: 668 • 2014 ACR/ARHP Annual Meeting
Evolution of Patients with Systemic Lupus Erythematous Treated with Belimumab in Clinical Practice Settings
Josefina Cortes¹, Carlos Marras², Jose Luis Andreu³, Jaime Calvo-Alen⁴, Angel M. Garcia-Aparicio⁵, Elvira Diez Alvarez⁶, Carlos Coronell⁷, Elena Morejon⁷, Alessandra Perna⁸, Volker Koscielny⁸ and Josep Ordi-Ros¹, ¹Internal Medicine, Vall d´Hebron Hospital, Barcelona, Spain, ²Rheumatology, Virgen de la Arrixaca Hospital, Murcia, Spain, ³Rheumatology, Puerta de Hierro Universitary Hospital, Madrid, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ⁶Rheumatology, Leon Hospital, Leon, Spain, ⁷Medical Department, GlaxoSmithKline, Madrid, Spain, ⁸Medical Department, GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose After the approval of belimumab for patients with systemic lupus erythematosus (SLE), the objective of this study is to describe the clinical outcomes associated…
Abstract Number: 2791 • 2014 ACR/ARHP Annual Meeting
Lung Cancer in SLE
Sasha Bernatsky¹, Rosalind Ramsey-Goldman², Michelle Petri³, Murray B. Urowitz⁴, Dafna D. Gladman⁴, Edward H. Yelin⁵, Christine Peschken⁶, John G. Hanly⁷, James E. Hansen⁸, Jean-Francois Boivin⁹, Lawrence Joseph¹⁰, Patrice Chrétien Raymer¹¹, Mruganka Kale¹², Ann E. Clarke¹³ and Systemic Lupus International Collaborating Clinics (SLICC)¹⁴, ¹Clinical Epidemiology - Rheumatology, McGill University, Montreal, QC, Canada, ²FSM-300, Northwestern University, Chicago, IL, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁶Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁷Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ⁸Therapeutic Radiology, Yale University, New Haven, CT, ⁹Department of Epidemiology & Biostatistics, McGill University, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ¹²Clinical Epidemiology Rheum, RI McGill Univ Health Ctr, Montreal, QC, Canada, ¹³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁴Systemic Lupus International Collaborating Clinics (SLICC), ON, Canada
Background/Purpose: Lung cancer is 50% more common in SLE patients than their sex and age-matched counterparts. Our objective was to assess lung cancer risk in…
Abstract Number: 2166 • 2014 ACR/ARHP Annual Meeting
Bim Suppresses the Development of Glomerulonephritis By Inhibiting M2 Polarization
Fu-Nien Tsai, Northwestern University, Chicago, IL
Background/Purpose Only recently have monocytes and macrophages been accepted as critical players in the pathogenesis of SLE. However, very little is known regarding the molecular…
Abstract Number: 1650 • 2014 ACR/ARHP Annual Meeting
Prevalence and Prognostic Implications of IgG4 in Membranous Lupus Nephritis
David Herrera Van Oostdam¹, Marco Ulises Martinez-Martinez¹, Cuauhtémoc Oros-Ovalle², David Martínez-Galla², Gerardo Tonatiu Jaimes-Piñón¹, Natalia Alemán-Sánchez² and Carlos Abud-Mendoza¹, ¹Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ²Patología, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
Background/Purpose: Patients with membranous lupus nephritis (MLN) have increased risk of thrombosis and different prognosis than other classes of lupus nephritis (LN). Previous studies demonstrated…
Abstract Number: 867 • 2014 ACR/ARHP Annual Meeting
Specific SLE Disease Manifestations in the Six Months Prior to Conception Predict Similar Manifestations during Pregnancy
Sara K. Tedeschi¹, Hongshu Guan¹, Alexander Fine¹, Bonnie L. Bermas² and Karen H. Costenbader², ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Active SLE, in particular lupus nephritis, during the six months prior to conception is associated with disease flare during pregnancy. Previous studies, however, have…
Abstract Number: 657 • 2014 ACR/ARHP Annual Meeting
Distinct Contributions of C1q and C3 in Preventing Immunogenicity of Apoptotic Cells in Lupus
Clayton Sontheimer¹, Yenly Nguyen², Keith B. Elkon³ and YuFeng Peng³, ¹Pediatric Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Defective clearance of apoptotic cells (AC) and complement deficiency are important contributors to the pathogenesis of systemic lupus. Dead (sunburn) cells and complement…
Abstract Number: 2737 • 2014 ACR/ARHP Annual Meeting
Microrna-155 Suppresses IL-21 Signaling and Production in Systemic Lupus Erythematosus
Tue K. Rasmussen¹, Thomas Andersen¹, Rasmus Bak¹, Gloria Yiu², Kristian Steengaard-Petersen³, Jacob G. Mikkelsen¹, Paul J. Utz⁴, Christian Holm¹ and Bent Deleuran^3,5, ¹Department of Biomedicine, Aarhus University, Aarhus C, Denmark, ²Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Department of Biomedicine, Aarhus University, Aarhus, Denmark
Background/Purpose IL-21 is a key regulator of B cells functions and autoantibody production and is mainly produced by follicular T helper cells. The purpose of…
Abstract Number: 2109 • 2014 ACR/ARHP Annual Meeting
Are Patient Ratings of Providers and Health Plans Associated with Technical Quality of Care in SLE?
Edward H. Yelin¹, Laura Trupin², Jinoos Yazdany² and Chris Tonner³, ¹Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³3333 California Street, Box 09, University of California, San Francisco, San Francisco, CA
Background/Purpose . Prior research has shown that the technical quality of SLE care is associated with the degree of subsequent accumulated damage. However, it is…
Abstract Number: 1647 • 2014 ACR/ARHP Annual Meeting
Relationship Between Apom/S1P Levels and Atherosclerosis in Women with Systemic Lupus Erythematosus
Sonali Narain¹, Sylvain Galvani², Christina Christoffersen³, Peiying Yang⁴, Maureen A. McMahon⁵, Timothy Hla² and Jane E. Salmon¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Vascular Biology, Weill Cornell College of Medicine, New York, NY, ³Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁴Gen Oncology Research, University of Texas MD Anderson Cancer Center, Houston, TX, ⁵Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: SLE patients are at risk for atherosclerotic cardiovascular disease (ASCVD). In some SLE patients, high density lipoprotein (HDL) has impaired vasoprotective effects, and this…
Abstract Number: 865 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Events Prior to or Early after Diagnosis of SLE
Murray B. Urowitz¹, Dafna D. Gladman¹, Nicole Anderson², Dominique Ibanez³ and Systemic Lupus International Collaborating Clinics (SLICC)⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Division of Rheumatology, University of Toronto, Toronto Western Hospital (Coordinating Center), Toronto, ON, Canada
Background/Purpose: A large multicenter multinational inception cohort was established to study risk factors for atherosclerosis (AS) in SLE. Previous studies have shown a history of…
Abstract Number: 651 • 2014 ACR/ARHP Annual Meeting
Inhibiting Tweak (TNF-like weak inducer of apoptosis) Signaling Improves Blood Brain Barrier Integrity and Protects from Neuronal Damage in Murine Neuropsychiatric Lupus
Jing Wen¹, Jessica Doerner¹, Ariel Stock², Jennifer Michaelson³, Linda Burkly³, Maria Gulinello² and Chaim Putterman⁴, ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Biogen Idec, Cambridge, MA, ⁴The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: While neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) is relatively common and appears early, the underlying mechanisms are not fully understood. The disruption of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].